Abeona Therapeutics (ABEO) Stock: Buy, Sell, or Hold?
ABEO - Abeona Therapeutics Inc. Common Stock
$4.40
-0.07 (-1.57%)
▼
5d:
-0.68%
30d:
-18.97%
90d:
-28.22%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
15d
Get Alerted When ABEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ABEO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: ABEO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ABEO is currently trading at $4.40, which is considered oversold relative to its 30-day fair value range of $4.72 to $5.52. From a valuation perspective, the stock is trading at a discount (Forward PE: -21.2) compared to its historical average (21.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ABEO is in a downtrend. The price is currently testing key support at $4.28. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABEO scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $18.88 (+329.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABEO is in a downtrend. The price is currently testing key support at $4.28. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABEO scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $18.88 (+329.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.72 -
$5.52
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 329.0% below Wall St target ($18.88)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 63/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$4.72 -
$5.52
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.28
Resistance Level
$4.95
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.20
Wall Street Target
$18.88
(+329.0%)
Revenue Growth (YoY)
2745.0%
Profit Margin
-246.4%
PE vs Historical
-21.2 vs 21.7
CHEAP
Share & Embed Analysis
Last updated: October 25, 2026 10:28 PM ET
Data refreshes hourly during market hours. Next update: 11:28 PM
Data refreshes hourly during market hours. Next update: 11:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
23 analysts |
$109 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$196 | 53 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$685 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
17 analysts |
$35 | 59 HOLD |
